Incyte Corporation
INCYIncyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Drugs in Pipeline
68
Phase 3 Programs
29
Upcoming Catalysts
29
Next Catalyst
Apr 1, 2026
4dMarket Overview
Stock performance and key metrics
29 upcoming, 1 past
Tafasitamab Phase 3 Results Expected
Primary completion for Tafasitamab trial (NCT05429268) in Large B-Cell Lymphoma
SourceLenalidomide Phase 3 Results Expected
Primary completion for Lenalidomide trial (NCT05429268) in Large B-Cell Lymphoma
Source27 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
ruxolitinib tablets
Polycythemia Vera
Povorcitinib
NonSegmental Vitiligo
Ruxolitinib Cream
Nonsegmental Vitiligo With Genital Involvement
Pemetrexed
Metastatic Squamous Non-Small Cell Lung Cancer
Itacitinib
MPN (Myeloproliferative Neoplasms)
pembrolizumab + epacadostat
Melanoma
Extracorporeal photopheresis (ECP)
Graft-versus-host Disease (GVHD)
Vehicle Cream
Prurigo Nodularis
Vehicle
Non-segmental Vitiligo
INCA034176
Chronic Graft-versus-host-disease
rituximab
Follicular Lymphoma
Ruxolitinib
MPN (Myeloproliferative Neoplasms)
Tacrolimus (Tac)
Graft-versus-host Disease (GVHD)
carboplatin
Squamous Cell Carcinoma of the Anal Canal
ibrutinib
Lymphoma
Hydroxyurea (HU)
Polycythemia Vera
Pembrolizumab
Head and Neck Cancer
Sunitinib
Renal Cell Carcinoma (RCC)
Lenalidomide
Large B-Cell Lymphoma
Epacadostat
Lung Cancer
Cyclophosphamide
Diffuse Large B-cell Lymphoma
Prednisone
Graft-versus-host Disease (GVHD)
Corticosteroids
Chronic Graft-versus-host-disease
Retifanlimab
Metastatic Merkel Cell Carcinoma
Tafasitamab
Diffuse Large B Cell Lymphoma
Bendamustine (BEN)
Diffuse Large B-cell Lymphoma
INCB123667
Ovarian Cancer
Investigator's choice of chemotherapy
Ovarian Cancer
INCA33890
CRC (Colorectal Cancer)
Ruxolitinib 1.5% cream
Vitiligo
INCAGN02385
Endometrial Cancer
INCAGN01949
Advanced Malignancies
Axatilimab
Chronic Graft-versus-host-disease
INCAGN02390
Melanoma
Best available Treatment (BAT)
Chronic Graft-versus-host-disease
R-CHOP
Non Hodgkins Lymphoma
Gemcitabine
Solid Tumors
Regorafenib
Pancreatic Cancer
INCB018424
Rheumatoid Arthritis
Osimertinib
Lung Cancer
INCB028050
Rheumatoid Arthritis
Prednisone or methylprednisolone
Graft-versus-host Disease (GVHD)
INCB001158
Biliary Tract Cancer (BTC)
MK-3475
Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
INCB177054
Solid Tumors
ICS-LABA
Moderate to Severe Asthma
Ruxolitinib Phosphate
Psoriasis
INCA000585
Immune Thrombocytopenia
Pemigatinib
Non-Small Cell Lung Cancer (NSCLC)
Immune effector cell therapy
Cytokine Release Syndrome
Ruxolitinib 25 mg
Multiple Myeloma
Nivolumab
B-cell Malignancies
Asparaginase Erwinia Chrysanthemi
Leukemia
Platinum-based chemotherapy
Lung Cancer
INCAGN01876
Advanced Malignancies
Capecitabine
Pancreatic Cancer
INCB013739
Type 2 Diabetes
INCB000928
Anemia
Ruxolitinib phosphate cream
Psoriasis
INCB054707
Hidradenitis Suppurativa
Parsaclisib
B-Cell Malignancies
Ponatinib
Philadelphia Positive
Ruxolitinib 0.15% Cream QD
Atopic Dermatitis
INCB009471
HIV Infections
parsaclisib + itacitinib
B-Cell Malignancies
Oxaliplatin
Solid Tumor
INCB099280
Advanced Solid Tumor
MEDI4736
Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ruxolitinib tablets | Phase 3 | Polycythemia Vera | - | - |
Povorcitinib | Phase 3 | NonSegmental Vitiligo | - | - |
Ruxolitinib Cream | Phase 3 | Nonsegmental Vitiligo With Genital Involvement | - | - |
Pemetrexed | Phase 3 | Metastatic Squamous Non-Small Cell Lung Cancer | - | Patent 2036 |
Itacitinib | Phase 3 | MPN (Myeloproliferative Neoplasms) | - | - |
pembrolizumab + epacadostat | Phase 3 | Melanoma | - | - |
Extracorporeal photopheresis (ECP) | Phase 3 | Graft-versus-host Disease (GVHD) | - | - |
Vehicle Cream | Phase 3 | Prurigo Nodularis | - | - |
Vehicle | Phase 3 | Non-segmental Vitiligo | - | - |
INCA034176 | Phase 3 | Chronic Graft-versus-host-disease | - | - |
rituximab | Phase 3 | Follicular Lymphoma | - | - |
Ruxolitinib | Phase 3 | MPN (Myeloproliferative Neoplasms) | - | Patent 2041 |
Tacrolimus (Tac) | Phase 3 | Graft-versus-host Disease (GVHD) | - | - |
carboplatin | Phase 3 | Squamous Cell Carcinoma of the Anal Canal | - | - |
ibrutinib | Phase 3 | Lymphoma | - | - |
Hydroxyurea (HU) | Phase 3 | Polycythemia Vera | - | - |
Pembrolizumab | Phase 3 | Head and Neck Cancer | - | - |
Sunitinib | Phase 3 | Renal Cell Carcinoma (RCC) | - | - |
Lenalidomide | Phase 3 | Large B-Cell Lymphoma | - | - |
Epacadostat | Phase 3 | Lung Cancer | - | - |
Cyclophosphamide | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
Prednisone | Phase 3 | Graft-versus-host Disease (GVHD) | - | - |
Corticosteroids | Phase 3 | Chronic Graft-versus-host-disease | - | - |
Retifanlimab | Phase 3 | Metastatic Merkel Cell Carcinoma | - | - |
Tafasitamab | Phase 3 | Diffuse Large B Cell Lymphoma | - | - |
Bendamustine (BEN) | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
INCB123667 | Phase 3 | Ovarian Cancer | - | - |
Investigator's choice of chemotherapy | Phase 3 | Ovarian Cancer | - | - |
INCA33890 | Phase 3 | CRC (Colorectal Cancer) | - | - |
Ruxolitinib 1.5% cream | Phase 2 | Vitiligo | - | - |
INCAGN02385 | Phase 2 | Endometrial Cancer | - | - |
INCAGN01949 | Phase 2 | Advanced Malignancies | - | - |
Axatilimab | Phase 2 | Chronic Graft-versus-host-disease | - | - |
INCAGN02390 | Phase 2 | Melanoma | - | - |
Best available Treatment (BAT) | Phase 2 | Chronic Graft-versus-host-disease | - | - |
R-CHOP | Phase 2 | Non Hodgkins Lymphoma | - | - |
Gemcitabine | Phase 2 | Solid Tumors | - | - |
Regorafenib | Phase 2 | Pancreatic Cancer | - | - |
INCB018424 | Phase 2 | Rheumatoid Arthritis | - | - |
Osimertinib | Phase 2 | Lung Cancer | - | - |
INCB028050 | Phase 2 | Rheumatoid Arthritis | - | - |
Prednisone or methylprednisolone | Phase 2 | Graft-versus-host Disease (GVHD) | - | - |
INCB001158 | Phase 2 | Biliary Tract Cancer (BTC) | - | - |
MK-3475 | Phase 2 | Microsatellite-instability (MSI) High Colorectal Cancer (CRC) | - | - |
INCB177054 | Phase 2 | Solid Tumors | - | - |
ICS-LABA | Phase 2 | Moderate to Severe Asthma | - | - |
Ruxolitinib Phosphate | Phase 2 | Psoriasis | - | - |
INCA000585 | Phase 2 | Immune Thrombocytopenia | - | - |
Pemigatinib | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | Patent 2040 |
Immune effector cell therapy | Phase 2 | Cytokine Release Syndrome | - | - |
Ruxolitinib 25 mg | Phase 2 | Multiple Myeloma | - | - |
Nivolumab | Phase 2 | B-cell Malignancies | - | - |
Asparaginase Erwinia Chrysanthemi | Phase 2 | Leukemia | - | - |
Platinum-based chemotherapy | Phase 2 | Lung Cancer | - | - |
INCAGN01876 | Phase 2 | Advanced Malignancies | - | - |
Capecitabine | Phase 2 | Pancreatic Cancer | - | - |
INCB013739 | Phase 2 | Type 2 Diabetes | - | - |
INCB000928 | Phase 2 | Anemia | - | - |
Ruxolitinib phosphate cream | Phase 2 | Psoriasis | - | Patent 2041 |
INCB054707 | Phase 2 | Hidradenitis Suppurativa | - | - |
Parsaclisib | Phase 2 | B-Cell Malignancies | - | - |
Ponatinib | Phase 2 | Philadelphia Positive | - | - |
Ruxolitinib 0.15% Cream QD | Phase 2 | Atopic Dermatitis | - | - |
INCB009471 | Phase 2 | HIV Infections | - | - |
parsaclisib + itacitinib | Phase 2 | B-Cell Malignancies | - | - |
Oxaliplatin | Phase 2 | Solid Tumor | - | - |
INCB099280 | Phase 2 | Advanced Solid Tumor | - | - |
MEDI4736 | Phase 2 | Solid Tumors | - | - |
Chronic Graft-versus-host-disease
3 drugs in this indication
Melanoma
2 drugs in this indication
MPN (Myeloproliferative Neoplasms)
2 drugs in this indication
B-cell Malignancies
2 drugs in this indication
Graft-versus-host Disease (GVHD)
2 drugs in this indication
Hidradenitis Suppurativa
2 drugs in this indication
Polycythemia Vera
2 drugs in this indication
Metastatic Squamous Non-Small Cell Lung Cancer
1 drug in this indication
Leukemia
1 drug in this indication
HIV Infections
1 drug in this indication
Biliary Tract Cancer (BTC)
1 drug in this indication
Type 2 Diabetes
1 drug in this indication
Philadelphia Positive
1 drug in this indication
Solid Tumors
1 drug in this indication
Non-Small Cell Lung Cancer (NSCLC)
1 drug in this indication
Prurigo Nodularis
1 drug in this indication
Psoriasis
1 drug in this indication
Follicular Lymphoma
1 drug in this indication
Metastatic Merkel Cell Carcinoma
1 drug in this indication
Moderate to Severe Asthma
1 drug in this indication
Non-segmental Vitiligo
1 drug in this indication
Multiple Myeloma
1 drug in this indication
Nonsegmental Vitiligo With Genital Involvement
1 drug in this indication
NonSegmental Vitiligo
1 drug in this indication
Diffuse Large B Cell Lymphoma
1 drug in this indication
Anemia
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Advanced Solid Tumor
1 drug in this indication
Lymphoma
1 drug in this indication
Squamous Cell Carcinoma of the Anal Canal
1 drug in this indication
Endometrial Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)